Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for HER2-positive Early Breast Cancer
NCT07565324Phase 2Not yet recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in HER2-positive breast cancer, sponsored by National Taiwan University Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07565324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565324.